Cancer Research UK supports additional TroVax phase II trial in colorectal cancerAugust 28, 2003Oxford BioMedica announced today that Cancer Research UK (CRUK) has agreed to conduct and sponsor an open label Phase II trial with Oxford BioMedica's leading cancer immunotherapy product, TroVax®, in colorectal cancer patients who have liver metastases. The decision by CRUK follows extensive review of the successful Phase I/II data of TroVax in colorectal cancer patients. This study is in addition to the two ongoing Phase II trials with TroVax in colorectal cancer alongside chemotherapy, and the planned trials in renal and breast cancer. The patient population in the CRUK Phase II trial will comprise twenty Stage IV colorectal cancer patients who are to undergo surgery for resectable liver metastases. Patients will receive injections of TroVax followed by surgery approximately two weeks later. Biopsies of the tumour will be taken at surgery and analysed for TroVax stimulated immune activity. Further vaccinations will be given after surgery. Patients' management will then continue as standard, usually including adjuvant chemotherapy. Patients will be followed after the final vaccination to assess immune responses and toxicity and then monitored over the longer term for clinical benefit. Commenting on the announcement, Oxford BioMedica's chief executive, Professor Alan Kingsman said, "Cancer Research UK is one of the world's leading cancer research organisations and is committed to the development of better cancer treatments for patients. Their involvement in this project provides further validation of Oxford BioMedica's advanced cancer immunotherapeutic." Northbank Communications |
|||||||||||||||||||||
| Related Colorectal Cancer Current Events and Colorectal Cancer News Articles 'Cross-talk' mechanism contributes to colorectal cancer Researchers at the University of Wisconsin-Madison School of Medicine and Public Health have identified a molecular mechanism that allows two powerful signaling pathways to interact and begin a process leading to colorectal tumors. African-Americans with colorectal cancer have poorer outcomes, lower survival rates New research published in the November issue of the Journal of the American College of Surgeons shows that African-American patients with colorectal cancer are more likely to be diagnosed with advanced disease and are less likely to undergo surgical procedures compared with Caucasians, suggesting that improvements in screening and rates of operation may reduce differences in colorectal cancer outcomes for African-Americans. Colon cancer screening more effective earlier in day, UCLA study finds The effectiveness of a screening colonoscopy may depend on the time of day it is performed. According to a new UCLA study, early-morning colonoscopies yielded more polyps per patient than later screenings, and fewer polyps were found hour by hour as the day progressed. 1 disease, not 1 demographic The Asian continent has nearly four billion people living in 47 different countries, and each of these groups has their own unique set of health issues. But when they come to the United States, they're often lumped into one large demographic: "Asian/Pacific Islander." Study shows unsedated colonoscopy for colorectal cancer screening well accepted by patients Researchers from Taiwan report in a new study that unsedated colonoscopy for primary colorectal cancer screening is well accepted in a majority of patients. M. D. Anderson redefines screening guidelines for breast, cervical and colorectal cancers Drawing on years of experience in cancer research and patient care, The University of Texas M. D. Anderson Cancer Center released today the most comprehensive, risk-based screening guidelines publicly available to date for breast, cervical and colorectal cancers. The bowels of infection Current research suggests that latent cytomegalovirus (CMV) infection may exacerbate inflammatory bowel disease (IBD). The related report by Onyeagocha et al, "Latent cytomegalovirus infection exacerbates experimental colitis," appears in the November 2009 issue of The American Journal of Pathology. How to Lower Costs, Waiting Times for Colonoscopies Colorectal cancer is a leading cause of cancer-related deaths in the United States, leading to over 50,000 fatalities every year. Excess body weight causes over 124,000 new cancers a year in Europe At least 124,000 new cancers in 2008 in Europe may have been caused by excess body weight, according to estimates from a new modelling study. Adding cetuximab to chemotherapy reduces advanced lung cancer death risk by 13 percent Patients with advanced non-small cell lung cancer who are given cetuximab (Erbitux) in addition to chemotherapy are 13% less likely to die than those who receive chemotherapy alone, regardless of which chemotherapy drug cocktail is used, new research finds. They also experience slower disease progression and an increased chance of tumour shrinkage. More Colorectal Cancer Current Events and Colorectal Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||